Evaluation of a Bone Conducted Vibration Device Designed for Motion Sickness Mitigation

The commercial BCV device did not affect the presence or absence of motion sickness during placebo or experimental conditions and had no effect on tracking task performance. During the second trial session, MSAQ scores were lower and time to nausea and failure were longer; however, observed increases in motion tolerance during the second trial sessions likely resulted from sensory adaptation and appeared to be unrelated to the BCV device. Patterson FR, Kaplan A, Gallimore D, Sherwood S, Horning D, Folga RV. Evaluation of a bone conducted vibration device designed for motion sickness mitigation. Aerosp Med Hum Perform. 2025; 96(11):993-999.